

Fatemeh Chalabianloo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7775590/publications.pdf>

Version: 2024-02-01

17
papers

239
citations

1040056

9
h-index

996975

15
g-index

22
all docs

22
docs citations

22
times ranked

241
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 550-555.	2.0	31
2	Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). <i>PLoS Medicine</i> , 2021, 18, e1003653.	8.4	29
3	Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). <i>BMC Infectious Diseases</i> , 2019, 19, 943.	2.9	28
4	Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 506-513.	1.9	20
5	Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 306.	2.9	14
6	Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017. <i>BMC Psychiatry</i> , 2020, 20, 119.	2.6	12
7	Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. <i>BMJ Open</i> , 2020, 10, e036860.	1.9	11
8	Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 44.	2.2	10
9	Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. <i>BMC Health Services Research</i> , 2020, 20, 352.	2.2	10
10	Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. <i>BJPsych International</i> , 2022, 19, 66-69.	1.4	9
11	Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 93.	2.2	8
12	Methadone serum concentrations and influencing factors: A naturalistic observational study. <i>Psychopharmacology</i> , 2019, 236, 3159-3167.	3.1	5
13	Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy. <i>Journal of Substance Abuse Treatment</i> , 2020, 113, 108004.	2.8	4
14	Effectiveness and Safety of Low-Threshold Opioid-Agonist Treatment in Hard-To-Reach Populations with Opioid Dependence. <i>European Addiction Research</i> , 2022, 28, 199-209.	2.4	4
15	Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 39.	2.2	3
16	Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 67.	2.2	3
17	Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. <i>Journal of Addictive Diseases</i> , 2023, 41, 53-63.	1.3	2